Processa pharmaceuticals announces successful completion of phase 1b safety evaluation of ngc-cap in patients with advanced cancer resulting in recommended phase 2 doses

Next generation capecitabine (ngc-cap) provides patients with 2-10 times greater exposure to its 5-fu cancer treatment metabolite than capecitabine administration
PCSA Ratings Summary
PCSA Quant Ranking